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INTRODUCTION
The acute increase in type 2 diabetes mellitus (T2DM) is one of the most serious medical problems today. T2DM patients 
were about 385 million in 2014 and increase to 592 million by 
2035.1,2 Furthermore, the global health expenditure for diabetes 
has been approximately 11% of total medical spending on adults 
in the world.1,2 T2DM is characteristic for the deterioration of pan-
creatic β-cell function and insulin resistance in the liver and periph-
eral tissues. A combination of these factors, T2DM has an over-
production of hepatic blood glucose, elevation of fasting blood 
glucose, and insufficient glucose uptake by muscle cells which 
would increase postprandial blood glucose.3 Furthermore, several 
pathophysiological impairments have played a role in the progres-
sion and development of T2DM, such as liver, muscle, dysfunction 
of pancreatic α-cells with elevated glucagon value, fat cells with 
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accelerated lipolysis and kidney with increased glucose reabsorp-
tion.1,2
 T2DM has a chronic elevation of blood glucose levels, re-
sulting in microvascular complications with neuropathy, retinopa-
thy, nephropathy, and macrovascular complications with ischemic 
heart disease, cerebrovascular disease, peripheral arterial disease.4 
Therefore, clinical research and therapy have been continued for 
the achievement of optimal glycemic control associated with opti-
mal management of body weight, blood pressure, and lipid levels 
for years. Recently, several new anti-diabetic medicines have been 
developed. They have some beneficial effects for lowering HbA1c, 
body weight, hypoglycemia incidence and others.5
 As to the history of endocrinology and diabetes, Elrick 
and colleagues revealed interesting findings. It was reported that, 
when an oral glucose tolerance test was conducted on a healthy 
person, markedly increased insulin secretion was observed com-
pared to an intravenous load test.6 From this report, it suggested 
the presence of incretin (intestine secretion insulin (INCRETIN)) 
as a substance that enhances insulin secretion in the intestinal mu-
cosa.
 Later gastric inhibitory polypeptide (GIP) was identified 
by purification of intestinal hormone and glucagon-like peptide-1 
(GLP-1) showing incretin action was reported.7 Successive studies 
revealed the role and mechanism of GLP-1.8
 The function of GIP-1 has been reported to have several 
functions as follows: stimulating insulin secretion, inhibiting 
glucagon secretion, promoting glucose production and glucose 
uptake in the liver, increasing glucose uptake and glycogen 
production in skeletal muscle, decreasing food intake for the 
central nerve and delay of gastric emptying and so on.
 Recently, an agent was developed for T2DM known as 
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). They 
have a remarkable efficacy and safety profile distinct from other 
anti-diabetic agents.9 GLP-1 RAs could decrease blood glucose 
level by several function or mechanism, which are an enhancement 
of glucose-induced insulin secretion, suppression of glucagon se-
cretion and delayed gastric emptying.10,11
 As described above, in recent years, GLP-1 RAs and 
DPP-4 inhibitors for diabetes have been widely used. Under 
these circumstances, the authors have been treating patients with 
lifestyle-related diseases including diabetes and obesity for many 
years.12-14 In particular, we have been conducting clinical research 
on low carbohydrate diet for numerous cases, research on metabo-
lism related to ketone bodies and carbohydrates, treatment of dia-
betes, etc., reporting on glucose limitation, blood glucose variation, 
ketone body and carbohydrate.14-16
 We recently administered dulaglutide that is one of GLP-
1 RA for two elderly patients with T2DM, which showed interest-
ing clinical course. Then we have described these cases and dis-
cussed in detail.
CASE REPORTS
Case 1
An 88-year-old male patient who has been formerly diagnosed with 
type 2 diabetes mellitus (T2DM) at the age of 73. Later he had been 
given oral medicine for years, and recently he got treated with insu-
lin administration twice by a mixed type of 3:7 in a different clinic. 
From 2014, he started getting treated at our diabetes department 
of  our hospital.
 On physical examination, he showed 163 cm in height, 
67 kg in weight, BMI 25.2 at first visit, and his vitals and con-
sciousness are normal, and lung, heart, abdomen and neurologi-
cal findings were unremarkable. Laboratory data were as follows: 
postprandial glucose-120 min 156 mg/dL, HbA1c was 7.4%, Hb 
11.4 g/dL, GOT 22 IU/mL, GPT 26 IU/mL, r-GTP 26 IU/mL, 
BUN 24 mg/dL, Cre 1.1 mg/dL, TG 334 mg/dL, LDL 117 mg/
dL.
 The patient had some other medical problems, such as 
hypertension, arteriosclerosis, benign prostate hypertrophy (BPH) 
and mild cognitive impairment (MCI) without difficulties of  Qual-
ity of  Life (QOL)/Activities in Daily Living (ADL) in daily life. 
He has been given several oral medicines including aspirin 100 mg, 
valsartan 20 mg and tamsulosin hydrochloride 0.2 mg. For the fine 
adjustment of  treatment for T2DM, glimepiride dosage from 0.5-3 
mg per day has been added according to the value of  HbA1c and 
daily profile of  blood glucose.
 
 Progress course of case 1 is shown in Figure 1. Until May 
2016, his control status of blood glucose was good and stable on 
the administration of liraglutide 0.9 mg/day. C-peptide indexes 
(CPI) were 2.5 and 3.3 which were satisfactory. Then, GLP-1 ana-
logue was switched from liraglutide to dulaglutide. The reason was 
that the injection can be lessened from once per day to once per 
week by the strong hope of the patient and family.
 After the switch of  the GLP-1 agent, the clinical course 
was stable for 3-4 months. However, a daily profile of  blood glu-
cose and HbA1c was gradually elevated. The patient was admit-
ted for hyperglycemia with blood glucose 394 mg/dL and HbA1c 
11.3% in October, 2016. After that, long-acting insulin glargine 
was applied for the treatment. HbA1c was good and stable for 8 
months until August, 2017. The patient and the family hoped again 
to change from glargine to dulaglutide for their inconvenience and 
forgotten the episode of injection every day.
 There was good glucose control for 3 months, but blood 
glucose and HbA1c was again elevated in December, 2017 with 
the value of 518 mg/dL and 11.1%, respectively. He was admitted 
and treated with enhanced insulin therapy by insulin glargine and 
humulin R, which are long-acting and short-acting insulin. After 
his improvement and discharge from the hospital, he has been on 
glargine 12-14 units/day. After the switch of  the GLP-1 agent, the 
clinical course was stable for 3-4 months. However, a daily profile 
of  blood glucose and HbA1c was gradually elevated. The patient 
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was admitted for hyperglycemia with blood glucose. As mentioned 
above, case 1 has been treated as basal supported oral therapy 
(BOT), which were glargine (insulin) and glimepiride (sulpho-
nylurea agent). The combination of liraglutide and sulphonylurea 
agent indicated satisfactory result for long months, but dulaglutide 
and sulphonylurea agent had an effect of  only about 3 months. 
Case 2
An 83-year-old male patient who has been treated as T2DM at 
another clinic for more than 20 years. He has been in the nursing 
home in recent few years. He was admitted to our hospital in  Oc-
tober, 2016 for further evaluation and treatment. 
 On physical examination, he showed 152 cm in height, 
40.3 kg in weight, BMI 17.4 at first visit, and his vitals and con-
sciousness are normal, and lung, heart, abdomen, and neurologi-
cal findings were unremarkable. Laboratory data were as follows: 
postprandial glucose-120 min 207 mg/dL, HbA1c was 8.5%, C-
peptide- immunoreactivity 5.2 ng/mL, CPI=1.35. Hb 11.0 g/dL, 
WBC 5200/μL, Plt 17.4x104 /μL, GOT 14 IU/mL, GPT 11 IU/
mL, r-GTP 11 IU/mL, LDH 163 IU/mL, BUN 29 mg/dL, Cre 
1.6 mg/dL, uric acid 3.7 mg/dL, Na 143 mEq/L, Cl 106 mEq/L, 
K 4.0 mEq/L, TG 83 mg/dL, HDL 31 mg/dL. 
 The patient has other medical problems, such as hyper-
tension, chronic heart failure, chronic renal failure and mild cogni-
tive impairment (MCI). Consequently, the list of oral medications 
per day were as follows: 1) linagliptin 5 mg qd., voglibose 0.3 mg 
tid., repaglinide 0.5 mg tid. for diabetes, 2) azosemide 60 mg qd., 
telmisartan 40 mg qd., amlodipine besilate 5 mg qd. and carvedilol 
5 mg qd. for hypertension and chronic heart failure, 3) febuxostat 
10 mg qd., calcium polystyrene sulfonate 50 g bid., calcitriol 0.5 µg 
qd., and epoetin beta pegol 50 μg per month for chronic renal fail-
ure, 4) esomeprazole magnesium hydrate 20 mg qd., donepezil hy-
drochloride 5 mg qd and clopidogrel sulfate 50 mg qd. for Gastro-
esophageal Reflux Disease (GERD), dementia and anticoagulation 
therapy. Progress course of case 2 is shown in Figure 2. Until May 
2017, his glycemic control had been good and stable on the ad-
ministration of degludec 3-5 unit/day. C-peptide index (CPI) was 
1.35 which seemed to be stable. HbA1c value increased to 8.0% 
in June 2017, and then dulaglutide was started for the expectation 
for improving glycemic variability and for convenient therapeutic 
injecting of GLP-1 analogue once per week by the hope of the 
patient and family.
 After starting dulaglutide in June 2017, the clinical course 
was stable and HbA1c value was decreased for 3 months. Howev-
er, in October, blood glucose and HbA1c were increased up to for 
3-4 months. However, daily profile and blood glucose and HbA1c 
were gradually increased. On November, postprandial glucose-120 
min and HbA1c were 592 mg/dL, and 11.2%. He was immediately 
admitted to the hospital on urgent basis.
 GLP-1 agent was discontinued and degludec and humu-
lin R was administered in order to maintain stable glucose vari-
ability. With this treatment, HbA1c was gradually decreased and it 
was 7.3 % in January 2018. Regarding the changes in body weight 
(Figure 2), it increased for a few months during twice treatment of  
degludec, and it decreased for a few months during treatment of  
dulaglutide.
 As mentioned above, case 2 had been treated as basal 
supported oral therapy (BOT), which were degludec (insulin) 
and glimepiride (sulphonylurea agent). Combination therapy of 
degludec and sulphonylurea agent revealed stable condition un-
til June, 2017. After that dulaglutide was first tried and seemed 
to show satisfactory effect. However, the efficacy has lasted only 
about 3 months, associated with the exacerbation of  blood glucose 
profile and HbA1c level. 
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Basal Information of GLP-1 and Dulaglutide
GLP-1 relies on insulin secretion and stimulates glucose. Several 
types of GLP-1 RA have been developed and have been clinically 
used. It is thought that GLP-1 RAs administered alone does not 
have a risk of hypoglycemia.17 GLP-1 RAs also promote weight 
reduction, probably through the suppression of appetite by the ac-
tivation of GLP-1 receptors in the brain.18,19 They can decrease 
blood pressure by increasing urinary sodium excretion with va-
sodilation, resulting in lowering blood pressure. GLP-1 RAs can 
improve postprandial hyperlipidemia by suppressing the produc-
tion of apolipoprotein B-48 and triglyceride absorption.10,11 Fur-
thermore, they can suppress inflammation responses by reducing 
production of inflammatory cytokines and macrophage infiltra-
tion.10,11 Therefore, GLP-1 RAs have indicated beneficial effects 
for decreasing blood glucose and weight reduction, blood pressure, 
lipid levels and inflammatory responses.
 Dulaglutide is a novel, long-acting GLP-1 RA which was 
developed as a once-weekly subcutaneous injection for the treat-
ment of T2DM (Eli Lilly and Company, USA).20 It consists of two 
GLP-1 analogs covalently linked by a small peptide to a human 
immunoglobulin G4 (IgG4-Fc) region-specific heavy chain. The 
GLP-1 moieties contain amino acid substitutions protecting from 
inactivation by dipeptidyl peptidase-IV (DPP-4), while the linker 
peptide is maintaining the potency of the GLP-1 analog. The hu-
man IgG4-Fc is modified by substituting several amino acids to 
reduce interaction with high-affinity Fc receptors, cytotoxicity, and 
immunogenicity.21 The half-life is approximately 5 days, and time 
to peak concentration after a single 0.75 mg dose is approximately 
3 days.
 Dulaglutide is a once a week formulation. The beneficial 
points are high blood glucose improving the effect, easy injection 
procedure, and low frequency of antibody appearance. It is also 
effective for patients who have poor compliance or cognitive im-
pairment and require nursing care and others. Concerning clinical 
efficacy, it showed a dose-dependent reduction in HbA1c and ac-
ceptable safety profile in the randomized, double-blind, placebo-
controlled, parallel-group, 12-week study.22
 
 Concerning dulaglutide, decrease in absorption rate and 
clearance after injection is found due to increase in molecular 
weight. Therefore, the half-life of blood concentration is extended 
to 4-5 days, and stable blood concentration can be maintained for 
1 week.23
 Dulaglutide is manufactured by Eli Lilly, where the trade 
name is Trulicity, and it has been approved by The European 
Medicines Agency (EMA) and the United States Food and Drug 
Administration (FDA).20.23 There are reports for the efficacy of du-
laglutide. Several studies have been reported as the Assessment of 
Weekly Administration of dulaglutide in Diabetes (AWARD) pro-
gram.20.23 As a study of dose setting, two-years of study was con-
ducted with AWARD-5.24 The standard dose has become 1.5 mg/
week in the United States and Europe. Meanwhile, 0.75 mg/week 
has been the standard usage method in Japan. HbA1c change was 
-1.60% at 26 weeks in 855 T2DM patients.25 There are 4 subgroups 
according to age (<65, >65) and BMI (<25, >65), in which elder/
light and elder/heavy subgroups revealed -1.68% and -1.72%, re-
spectively.26
 One year clinical research was carried out, resulting 
from the improvement of HbA1c was found at 14-52 weeks with 
-1.65%±0.13%.27 Furthermore, there was randomized, open-label, 
parallel-group, 26-week study with 361 patients with T2DM re-
ceiving sulphonylureas and/or biguanides, in which dulaglutide or 
glargine were added and compared in 2 groups. The decrease in 
HbA1c after 26 weeks was -1.44% vs. -0.90%, respectively, with a 
significant difference.28
 Effects of once-weekly dulaglutide on kidney function 
in patients with T2DM was investigated in phase II and III clini-
cal trials.29 Integrated data from 2005 T2DM patients were used 
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to evaluate the influences on estimated glomerular filtration rate 
(eGFR), urine albumin-to-creatinine ratio (UACR) and kidney 
adverse events (AEs). The results were dulaglutide treatment for 
T2DM did not affect eGFR and slightly decreased albuminuria.
DISCUSSION
In this report, two cases seemed to show an attenuated effect of 
GLP-1 RAs in a few months. This may be related to the function 
of GLP-1 RAs including short-acting and long-acting types.
 In general, GLP-1 RAs are categorized into 2 groups, 
which are short- and long-acting agents according to their half-
lives. They would change the mechanism of function for glucose 
lowering effects.30,31 The former seems to act mainly on gastric 
motility and lowers blood glucose after meals. On the other 
hand, the latter mainly acts on the pancreas to regulate insulin 
and glucagon secretion, thereby leading to stabilization of blood 
sugar. In addition, it is pointed out that the high-molecular-weight 
formulations found in some long-acting forms may attenuate 
the appetite suppressing effect due to the passage of brain blood 
barrier.32,33
 Actually, several studies of GLP-1 RAs have been re-
ported. In previous studies, long-acting liraglutide was found to 
be rather superior to the short-acting exenatide, comparing the 
achievement of composite end-points.34
 Recently, there are lots of studies reported on short-act-
ing (exenatide, lixisenatide) and long-acting GLP-1RAs (liraglutide, 
exenatide long-acting release, albiglutide, dulaglutide and semaglu-
tide).35-38 These agents are available in the clinical settings, allow-
ing comparison of the study of composite end-points in future. 
Moreover, long-acting GLP-1 RAs seem to have weight reduction 
effects according to their molecular weight and permeability across 
the blood-brain barrier, possibly by affecting their accessibility to 
GLP-1 receptors in the brain.39,40 Through various cases  treated 
with GLP-1 RAs, further investigation would be expected con-
cerning pathophysiological comparison and difference between 
long-acting and short-acting agents.
 As to dulaglutide study, 492 T2DM cases were studied 
for 26 weeks in 3 groups including dulaglutide 0.75 mg/week, lira-
glutide 0.9 mg/day and placebo.41 Changes in HbA1c were -1.43%, 
-1.33%, and -0.14%, respectively, in which the former two were 
equivalent.41
 Fasting blood glucose levels were -39.2 mg/dL, -39.8 
mg/dL, +1.0  mg/dL, respectively, with equivalent efficacy. Inter-
estingly, the group of dulaglutide 0.75 showed a decrease in urinary 
albumin excretion rate and triglyceride value compared to placebo. 
Regarding the adverse effects, several symptoms were observed 
such as nasopharyngitis, gastrointestinal symptoms, constipation, 
diarrhoea, nausea and decreased appetite. As pancreatic enzymes, 
amylase, and lipase were slightly elevated, and the increase of lipase 
was 18.5%, 29.8%, 4.9% in the three groups, respectively. Anti-
body at dulaglutide 0.75 appeared at only 1.1%, but no neutralizing 
antibody appeared.41
 Subsequently, in the 52-week study, the two groups of 
dulaglutide 0.75 mg/week and liraglutide 0.9 mg/day showed 
-1.39% and -1.19%, respectively, with slight superiority in the for-
mer.42 In western countries, these two agents have been used twice 
daily.. According to the results of AWARD-6, the two groups of 
dulaglutide 1.5 mg/week and liraglutide 1.8 mg/day at 26 weeks 
showed the changes in HbA1c, which are equivalent to -1.42% and 
-1.36%, respectively.40
 In AWARD-9 study, the addition of weekly dulaglutide 
vs. the addition of placebo to titrated glargine was compared.43 
Subjects were 300 T2DM and phase III, double-blind, parallel-
arm, placebo-controlled study were randomized to weekly subcu-
taneous injections of dulaglutide 1.5  mg or placebo with titrated 
daily glargine. The results were that decrease HbA1c at 28 weeks 
was -1.44% with dulaglutide/glargine and -0.67% with placebo/
glargine with significant difference (p<0.01). The hypoglycemia’s 
rate was 7.69 and 8.56, respectively without any difference. These 
findings suggest that weekly dulaglutide 1.5  mg added to basal in-
sulin would be an efficacious and well-tolerated treatment option 
for patients with T2DM.43
 As mentioned above from the study on dulaglutide once 
a week by injection, blood glucose and HbA1c for T2DM are de-
creased with enough efficacy. Furthermore, adverse effects are not 
clinically significant. Judging from the clinical outcome to the third 
phase internationally, dulaglutide seems to be effective and safe 
GLP-1 RA. It will be useful for diabetic patients of all pathological 
conditions pharmacologically. Especially, it can be applicable for 
young and elderly patients with some impairment and dementia 
with some impairment and dementia with insufficient QOL/ADL 
ability.
 As current 2 cases, recent treatment of type 2 diabetes has 
moved from the previous Basal Supported Oral Therapy (BOT) 
to a new Basal supported post- Prandial GLP-1 therapy (BPT). 
The former is basal insulin + oral medicine, and the latter is basal 
insulin + GLP-1 RA treatment.
 There is a comparison study between BOT and BPT. For 
the comparison group, 557 T2DM patients were classified into 2 
groups.44 Degludec/liraglutide group and glargine group showed 
that basal HbA1c as 8.4% vs. 8.2%, the changed HbA1c at 26 
weeks as -1.81% vs. -1.13% respectively with meeting criteria for 
non-inferiority (p<0.001) and confirmed hypoglycemic episodes as 
2.23 vs. 5.05 per year with estimated rate ratio as 0.43 (p<0.001). 
 Consequently, BPT may have a superior effect than 
BOT, and benefits of BPT include stabilization of blood glucose 
fluctuation and good health-related quality of life (HRQOL).
 HRQOL and cost-effectiveness have been also impor-
tant aspects in addition to management of glycemic control for 
prevention of diabetic complications. GLP-1 RAs are treated by 
injections, which sometimes decrease HRQOL for the patients. 
Moreover, considerably higher medical costs are needed com-
pared with that of oral anti-diabetic drugs. There are few reports 
concerning HRQOL and medical costs regarding GLP-1 RAs so 
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far, expecting the future development of clinical administration 
study.35,36 Expecting the future development of  clinical administra-
tion studies. 
 Liraglutide therapy is necessary to receive a once-daily 
injection. In contrast, other long-acting GLP-1 RAs are given by 
injection only once weekly. This merit may bring better adherence 
and prevent the deterioration of HRQOL.
 Combined therapy of basal insulin and GLP-1 RAs 
which is called BPT, has been recently gaining attention due to 
their beneficial and complementary action.45,46 When GLP-1 RAs 
are added to insulin treatment, the effects would include weight re-
duction without increasing hypoglycemic risk, in comparison with 
the insulin treatment with increased dosage. In the recent meta-
analysis, BPT decreased HbA1c value which is similar to basal-
bolus insulin therapies.46 Furthermore, BPT can improve HRQOL 
by reducing injection frequency. For T2DM patient with severely 
reduced β-cell function, the combined therapy can give beneficial 
effects and achieve optimal glycemic control by GLP-1 RAs.45,46 In 
order to have optimal glycemic control, the extent remaining β-cell 
function would be speculated according to the actual dosage units 
of insulin and GLP-1 RAs.
 The long-acting type slowly acts on pancreatic β-cells, 
improves insulin secretion ability, and tends to improve blood 
glucose control. In fact, any GLP-1 RA can be selected on a case-
by-case basis, including differences in devices or syringes.
In summary, we reported that 2 T2DM cases showed an attenuated 
effect of dulaglutide in a few months. For this clinical situation, 
several possibilities might be speculated as follows:
1) Antibody production could be considered. The frequency of 
appearance of dulaglutide anti-drug antibodies was very rare, 
where only 1 out of 136 cases28 and 3 out of 281 cases.41 Then, it is 
not likely due to antibody production in 2 cases.
2) GLP-1 RAs were made from human-origin and lizard-origin 
(exendin-4). The former includes that 1 mal/day in liraglutide and 
1 mal/week in dulaglutide, and the latter includes that 1 mal/ day 
in exenatide (byetta)/lixisenatide (liximia), and exenatide (videlion) 
in 1 mal/week. Since dulaglutide is human-origin, it does not prob-
ably influence the formation of an antibody. Moreover, there has 
not been clarified whether these two agents have any difference of 
function.
3) The changes in body weights of  2 cases were found, where they 
increased during treatment of  liraglutide, glargine and degludec, 
and they decreased during treatment of  dulaglutide. The latter 
would be one of  the merits of  dulaglutide that has been reported 
so far.18,19,39,40,45,46 However, it is not known whether it has any rela-
tions with clinical efficacy or any other adverse effects. This point 
would be further evaluated through clinical studies.
4) Current two cases have seemed to have similar pathophysiologi-
cal problems, such as late elderly person, a little impaired cognitive 
function and declined renal function. In the clinical course, they 
have not suffered from any changes of  nutritional or hepatic func-
tion, or inflammatory status during the period. Any remarkable 
changes have not found which were related to subacute exacerba-
tion of  glycemic control.
5) There is a possibility of  the subacute decreased ability of  insulin 
secretion in the β-cell. We had measured C-peptide index (CPI) a 
few times which may give a key to the changed pathophysiological 
situation. In the cases, we would consider all possible related fac-
tors influencing to insulin secretion, administration of  insulin and 
GLP-1 RAs and others.
CONCLUSION
This report described 2 cases of T2DM which showed interesting 
clinical course. The effect of dulaglutide that is one of the GLP-1 
RAs was attenuated in a few months. We speculated the possibili-
ties related to the function and comparison of GLP-1 RAs. GLP-1 
RAs treatment is increasing widely in the clinical practice, expect-
ing that this report would be useful resource for management of 
the T2DM.
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administration and expert in the medical/legal specialty. We have 
discussed and made confirmation that this study is valid and agreed 
with all members without any problems. Furthermore, informed 
consents and written paper agreements have been obtained from 
both the subjects.
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